Hormone and tetuzumab for active thyroid eye disease
Treatments studied
Part of Eyes & vision, Genetic & congenital, Hormones & metabolism, Immune system & allergy clinical trials.
This trial tests a new sequence of hormone therapy followed by a targeted drug (tetuzumab) for people with moderate to severe thyroid eye disease that is still active after steroid treatment didn't help enough.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with thyroid eye disease (TED).
- Your TED is moderate to severe, and still active (with a CAS score of 4 or more out of 7).
- You have already tried steroid treatment but it did not work well enough.
- You have not had radiation or surgery to the eye socket for TED.
- You do not have current serious vision-threatening complications or unstable medical conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a medication called IBI311 for people with inactive thyroid eye disease that still causes bothersome symptoms like double vision or trouble closing the eyes. The goal is to see if it helps improve these problems safely.
This trial tests a new medicine called MHB018A for people with active, moderate to severe thyroid eye disease. It aims to see if the drug can reduce eye symptoms like bulging and inflammation.
This trial tests a two-step treatment for active, moderate-to-severe thyroid eye disease (TAO). You will first receive hormone therapy, followed by a drug called IBI311. The goal is to see if this sequence works better for people who have not had steroid treatment before.
This study aims to build a model that helps doctors predict how thyroid eye disease (TAO) will progress, specifically for patients with moderate to severe symptoms. If you have had TAO and meet the activity criteria, your participation could lead to better personalized care.
This study tests a combination of two drugs, tocilizumab and flupentixol-melitracen, in people with active, moderate-to-severe thyroid-associated eye disease (TED). It aims to see if this combination can reduce eye bulging, double vision, and anxiety symptoms.
This study tests a drug called teprotumumab for people with active thyroid eye disease. It is designed to help reduce eye bulging and other symptoms, and may be an option if you have not had strong treatments before.
Hear when a new Thyroid Associated Ophthalmopathies trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.